News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioForest
FDA Cites GlaxoSmithKline for “Misleading” Letters
November 27, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON - Government regulators have criticized GlaxoSmithKline for downplaying the risks of its breast cancer drug Tykerb, while exaggerating the benefits in letters to doctors.
Twitter
LinkedIn
Facebook
Email
Print
GlaxoSmithKline
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
·
4 min read
·
Lorenzo Soliman
BioForest
ADC-Focused ProfoundBio Raises $112M in Oversubscribed Series B
February 14, 2024
·
2 min read
·
Tyler Patchen
BioForest
How the Pandemic Shifted the Rules of Recruiting
October 25, 2023
·
4 min read
·
Amanda Heidt
Bio NC
BioSpace Releases Exclusive Hotbed Maps
January 5, 2023
·
4 min read
·
Lisa Munger
